Lee MW, Kang D, Lim HK, et al. - Researchers conducted a study by utilizing a large longitudinal hospital registry and clinical factors correlated with overall survival and LTP in order to assess the 10-year overall survival and local tumor progression (LTP) of percutaneous radiofrequency ablation (RFA) for single nodular hepatocellular carcinoma (HCC) < 3 cm. They analyzed a total of 467 newly diagnosed individuals with single nodular HCC < 3 cm undergone RFA as first-line therapy from January 2008 to December 2016. The 5- and 10-year overall survival measures following RFA were 83.7% and 74.2%, respectively. After RFA, LTP (hazard ratio (HR), 2.03) was one of the significant factors for overall survival. It was found that ten-year therapeutic results of percutaneous RFA as first-line therapy were great for single HCC < 3 cm. Moreover, the periportal and subphrenic location of HCCs and tumor size were predictors for the development of LTP after RFA.